Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo.
Low molecular weight heparin fractions (LMWH) are less hemorrhagic but are as effective as standard heparin (SH) in preventing experimentally-induced venous thrombosis. The effect of LMWH in preventing extension of established thrombi is unknown. We have compared the effects of two LMWH's (CY, PK), and a low molecular weight heparinoid (a dermatan/heparan/chondroitin mixture, OH) with SH on the prevention of extension of established venous thrombi, by measuring their ability to inhibit the accretion of 125I-fibrin onto venous thrombi pre-formed in rabbit jugular veins. Anticoagulant activity was assayed ex vivo by the APTT and a chromogenic anti-Xa assay, and the antithrombotic effect of these glycosaminoglycans was related to their anticoagulant effects. Autologous thrombi were formed in both jugular veins of each rabbit. The rabbits were then injected with 125I-fibrinogen and treated with a bolus dose of glycosaminoglycan or saline, followed by a continuous infusion for 4 hours. All four glycosaminoglycans significantly inhibited 125I-fibrin accretion (p less than 0.001). SH, CY and PK were equipotent at doses of 42.5-62.5 anti-Xa U/kg/hr in preventing fibrin accretion by 50%. Higher doses had no further effect. OH was significantly more potent than the other three glycosaminoglycans at any given dose (p less than 0.005). There was no correlation between the antithrombotic effect and the anticoagulant effects. We conclude that these LMWH's are as effective as SH in preventing extension of established thrombosis.
D000818:Animals; D000925:Anticoagulants; D004195:Disease Models, Animal; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006025:Glycosaminoglycans / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008297:Male; D011817:Rabbits; D013329:Structure-Activity Relationship; D013924:Thrombophlebitis / Q000517:prevention & control*
D000925:Anticoagulants; D006025:Glycosaminoglycans; D005337:Fibrin; D005340:Fibrinogen; D006493:Heparin